Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CuraGen Corporation
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
August 12th, 2008
CuraGen Corporation (NASDAQ:CRGN), a clinical-stage biopharmaceutical company focused on oncology, reported its financial results for the second quarter of 2008 and updated clinical progress of CR011-vcMMAE. For the quarter ended June 30, 2008, CuraGen reported income from continuing operations of $39.3 million, or $0.69 per share, compared to a loss from continuing operations of $21.6 million, or $0.39 per share, during the same period in 2007. For the six months ended June 30, 2008, CuraGen reported income from continuing operations of $32.5 million or $0.57 per share, as compared to a loss from continuing operations of $37.5 million or $0.67 per share, during the...
Source: Cancer Weekly (2008-08-12)
|
